Moreover, targeting the signaling pathways activated by HBx, such as the Wnt/β‐catenin or TGF‐β pathways, has been proposed as a promising strategy for treating HBV‐related HCC. The gene discussed is TGFB1; the disease is hepatocellular carcinoma.